Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neoplas Med

Request full access

Based on the INP research into plasma medicine, the emerging company develops innovative products for medical applications

Greifswald, GermanyFounded 2009Health Tech & Medtech

About Neoplas Med

Neoplas Med GmbH is a German medical technology company established in 2009 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP) in Greifswald. The company leverages foundational research from the INP to create products for medical applications, operating within the growing plasma medicine market. This market, focused on wound care, is projected to expand significantly, driven by an aging population and the rising prevalence of chronic diseases.

The company's business model centers on the development, production, and sale of its cold plasma devices to healthcare providers. Its primary clientele includes university clinics, hospitals, and medical practices. Revenue is generated through the sale of the kINPen® MED device and associated sterile components. Neoplas Med has secured significant investment to scale its operations, with Niterra Ventures Company being a key strategic partner, investing a total of $25 million across several funding rounds to support international expansion and technology development.

The flagship product is the kINPen® MED, a handheld atmospheric pressure plasma jet. This was the first device of its kind to receive CE marking for treating chronic wounds and pathogen-induced skin disorders and is also MDR certified, a standard met by only a small percentage of European MedTech companies. The device works by applying a jet of cold argon plasma, at a temperature below 40°C, to the wound surface without direct contact. This process has a triple-action effect: it inactivates a broad spectrum of pathogens, including multi-resistant bacteria like MRSA; it promotes microcirculation to improve nutrient and oxygen supply; and it stimulates tissue regeneration. Clinical studies have demonstrated that this technology can reduce wound healing time by up to 50% compared to conventional methods, with no known side effects or risk of developing resistance. The precise, pen-like application makes it suitable for complex wounds with cavities and uneven surfaces.

A significant milestone was the approval for a trial study by Germany's Federal Joint Committee (G-BA) in 2021, a crucial step towards reimbursement by statutory health insurance, based on promising clinical data. The technology is currently used in 75% of German university clinics and has been utilized in over 500,000 treatments globally, with a presence in leading clinics across Europe and the Middle East. Ulrike Sailer has served as the CEO and managing partner since the end of 2019.

Source: Dealroom company data

At a glance

Status
Operational
Employees
27
Open positions
None listed
Dealroom signal
80.6/100
Industry
Health
Sub-industry
Medical Devices
Sector
Spinout, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Nov 2024 $18M $72M Venture Lab Niterra ↗
SEED✓Equity / VC Jan 2022 $7M $28M Venture Lab Niterra ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearProfitMargin
2026 —
2025 —
2024 —
2023 —
2022 —
2021 —
2020 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Neoplas Med website traffic

Latest recorded traffic for Neoplas Med is 3.6K monthly website visits, up 125% over the last three months. Neoplas Med's team grew 17.4% over the past year.

Latest monthly visits3.6K 3-month web change+125% 1-year team growth+17.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Neoplas Med in the Greifswald ecosystem

Live from Dealroom

The Neoplas Med office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Venture Lab Niterra

Other known investors2 additional known investors

  • Leibniz Association
  • Leib­niz In­sti­tu­te for Plas­ma Sci­ence and Tech­no­lo­gy
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇩🇪 Germany96.2%
🇦🇪 United Arab Emirates3.9%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neoplas Med on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neoplas Med’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.